In addition, levels of EphA2 and PGRN significantly predicted CTO (AUC > 0.6, p < 0.05), suggesting the potential diagnostic efficiency of circulating EphA2 and PGRN levels in evaluating the atheroma burden in patients with CAD, which further confirms the roles of EphA2 and PGRN in the progression of atherosclerosis. This evidence concerns the gene EPHA2 and atherosclerosis.